{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 28,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/26",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.26,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "image",
      "text": "Apexigen",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3286bbf6-666b-4d2d-a33c-21901f3b3341",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.92,
        "x": 0.04,
        "y": 0.43
      },
      "kind": "list",
      "text": "PRODUCT: Potentially first-in-class and best-in-class CD40 agonist. CLINICAL DATA: Established single-agent activity, validated target, validated molecule; encouraging interim Phase 2 data. FOCUS: Progressing broad Phase 2 program; seeking Type C meeting with the FDA mid 22 to determine registrational path",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a39a18c-2a66-4cbb-bda1-69b60b1b14a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "list",
      "text": "PARTNERSHIPS: Validated platform; non-dilutive funding. MILESTONES: Multiple value-driving milestones over next ~12-18 mos.",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70127fa5-8e08-428f-be67-978668dd7009",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.76,
        "x": 0.12,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Broad sotigalimab clinical program, 2 preclinical programs, additional programs in research",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02d14ccf-c2cf-4614-b329-3296c9c7720f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.54,
        "x": 0.23,
        "y": 0.29
      },
      "kind": "paragraph",
      "text": "Rich, differentiated, prolific APXiMAB antibody discovery engine",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d456e4c1-7188-4e21-adce-925003765edc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.14,
        "x": 0.43,
        "y": 0.37
      },
      "kind": "title",
      "text": "SOTIGALIMAB",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fbfc67b-9e29-4265-a7d0-99655b024c1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "title",
      "text": "PLATFORM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e02fb6c-9681-442d-a936-f23c28c88e61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.08,
        "x": 0.46,
        "y": 0.68
      },
      "kind": "title",
      "text": "PIPELINE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3cc3d4a-6fa8-4b0e-9605-6dc4c5c9c606",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "c21c8780-f795-4dad-92af-f7690e9fc49a",
      "evidence": "list/comparison: PRODUCT: Potentially first-in-class and best-in-class CD40 agonist. CLINICAL DATA: Established single-agent activity, validated target, validated molecule; encouraging interim Phase 2 data.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}